Impact of Bosentan in Ameliorating Methotrexate-Induced Tongue Toxicity in Rats

Background and objective: Although methotrexate has been utilized over many years, adverse effects are frequent throughout therapy, especially among cancer patients. The study examined the efficacy of bosentan as a protective therapy against tongue toxicity induced by methotrexate. Methods: This study employed twenty-four 300–400 g Wister-albino rats. The animals were categorized into three groups: methotrexate (80 mg/kg), methotrexate (80 mg/kg) plus bosentan (60 mg/kg), and control healthy (distilled water). The tongue mucosa was subjected to biochemical and immunohistochemical analysis. The animals' tongue mucosa was dissected immediately following they were euthanized on day 16. Results: In contrast to the control group, the Methotrexate group had significantly higher levels of TNF-α, IL-1β and MDA (p < 0.05). However, the Methotrexate+Bosentan group displayed considerably lower levels of TNF-α, IL-1β and MDA in contrast to the Methotrexate group, (p < 0.05). Conclusion: These findings demonstrate that bosentan protect considerably against methotrexate-induced tongue toxicity in rats.